Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

BioScience Health Innovations (BHIC) EPS (Weighted Average and Diluted) (2023 - 2025)

BioScience Health Innovations (BHIC) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.02 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 2290.12% to -$0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.06 through Dec 2025, up 530.8% year-over-year, with the annual reading at $0.06 for FY2025, 500.0% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.02 at BioScience Health Innovations, down from -$0.0 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.01 in Q3 2024, with the low at -$0.02 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 3 years is $0.0, with a median of $0.0 recorded in 2024.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 875.4% in 2025, while the deepest fall reached 2290.12% in 2025.
  • Over 3 years, EPS (Weighted Average and Diluted) stood at -$0.0 in 2023, then soared by 180.35% to $0.0 in 2024, then plummeted by 2290.12% to -$0.02 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.02, -$0.0, and $0.01 for Q4 2025, Q3 2025, and Q2 2025 respectively.